English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Brevundimonas diminuta (B. diminuta), which is rarely held responsible for human infections, is known to cause serious infections such as bacteremia in addition to causing urinary tract infection and emphysema in immunosuppressed individuals. B. diminuta, creates difficulties in the treatment due to its wide antibiotic resistance. In our study, a 78-year-old male dialysis patient with type-2 diabetes mellitus and chronic renal failure (CRF) was presented. Upon detecting fever, cefixime was started for treatment. Brevundimonas diminuta/vesicularis was isolated from the urine culture and confirmed by MALDI-TOF (Matrix Assisted Laser Desorption IonizationTime Of Flight) to B. diminuta. Amikacin, imipenem, piperacillin/tazobactam (TZP) and trimethoprim/sulfamethoxazole (SXT) were found sensitive in manual antibiotic susceptibility test (AST). SXT was given to the patient, who did not respond to cefixime therapy, and the patient was cured. We think that, SXT, TZP and imipenem can be used in the treatment of B. diminuta infections where AST results cannot be obtained from automated systems.

A Rare Urinary Tract Infection Agent in a Dialysis Patient: Brevundimonas diminuta